Company’s non-invasive breath analysis technology recognized for its innovation and potential to disrupt glucose monitoring industry.
San Bruno, Calif. – October 29, 2019 – Medical technology company BOYDSense, Inc. has returned from the RESI (Redefining Early Stage Investments) conference in Boston with a second-place finish in the RESI Innovation Challenge and myriad accolades from both investors and attendees at the event, one of the year’s biggest investment conferences for biotech and medtech. The company’s g-Sense Breath Meter, a handheld device designed to accurately predict blood glucose values by measuring the volatile organic compounds (VOCs) in human breath, was selected as a finalist and ultimately a winner from among 130 entries.
“Being one of the top finishers at this prestigious industry event confirms what our leadership team and current investors already know—that BOYDSense’s technology is poised to play a pivotal role in the transition to non-invasive monitoring of diabetes and other chronic conditions,” said BOYDSense CEO Bruno Thuillier.
BOYDSense was among 350 biotech startups and 350 investors that attended the annual event, which was organized by Life Science Nation. The 2019 RESI Innovation Challenge is open to global early-stage companies from across biotech, medtech, diagnostics, and digital health. From the initial 130 entries, 38 finalists were hand-selected by Life Science Nation’s scientific review board to present their technologies during the conference, and the winners were chosen based on votes from attendees.
Thuillier and BOYDSense VP of Product Management Joel Rabasco presented BOYDSense’s groundbreaking VOC biomarker technology in an exhibition format, sharing with investors and other attendees how the technology will greatly enhance the user experience and lower traditional barriers through a discreet handheld device that harnesses breath for pain-free diabetes monitoring.
“Both the second-place award from the RESI Innovation Challenge itself and the enthusiasm we received from investors and peers significantly boosted the momentum BOYDSense needs to continue on the path to bringing our first commercial product to market and into the hands of people with diabetes,” said Thuillier.
